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General Experimental Details 
Chemicals were purchased and used without further purification. All oligonucleotides used 
were purchased from Eurogentec (Belgium), purified by HPLC and delivered dry. 
Oligonucleotide concentrations were determined by UV-absorbance using a NanoDrop 2000 
Spectrophotometer from Thermo Scientific. Dry solvents were obtained by distillation using 
standard procedures, or by passage through a column of anhydrous alumina using equipment 
from Anhydrous Engineering (University of Bristol) based on the Grubbs’ design.1 Reactions 
requiring anhydrous conditions were performed under N2; glassware and needles were either 
flame dried immediately prior to use, or placed in an oven (150 °C) for at least 2 h and 
allowed to cool in a desiccator or under reduced pressure. Liquid reagents, solutions or 
solvents were added via syringe through rubber septa; solid reagents were added via Schlenk 
type adapters. Reactions were monitored by TLC on Kieselgel 60F254 (Merck), with UV light 
(254 or 365 nm) detection and either by charring with 10% sulfuric acid in ethanol, staining 
with ninhydrin or staining with PPh3 and then ninhydrin. Flash column chromatography was 
performed according to Still and co-workers,2 using silica gel [Merck, 230−400 mesh (40−63 
µm)]. The crude material was applied to the column by pre-adsorption onto silica, as 
appropriate. Reverse phase flash chromatography was performed on a Teledyne Isco 
Combiflash purification system, with RediSep Rf Gold C18 cartridges.  Solvents for flash 
column chromatography (FCC) and thin layer chromatography (TLC) are listed in 
volume:volume percentages. Extracts were concentrated in vacuo using both a Heidolph Hei-
VAP Advantage rotary evaporator (bath temperatures up to 50 °C) at a pressure of 15 mmHg 
(diaphragm pump) or 0.1 mmHg (oil pump), as appropriate, and a high vacuum line at room 
temperature. Water soluble compounds were freeze dried on a Lytotrap Plus (LTE Scientific 
LTD). 1H NMR and 13C NMR spectra were measured at 25°C in the solvent specified with 
Varian or Bruker spectrometers operating at field strengths listed. Chemical shifts are quoted 
in parts per million with spectra referenced to the residual solvent peaks. Multiplicities are 
abbreviated as: br (broad), s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), m 
(multiplet) and app. (apparent) or combinations thereof. Assignments of 1H NMR and 13C 
NMR signals were made where possible, using COSY, HSQC and HMBC experiments. 19F 
NMR spectra were recorded with 2-fluorobenzoic acid present as an internal standard to 
quantify the amount of TFA. For TFA quantification, the integration of the internal standard 
was compared with TFA in 19F NMR and the cation in 1H NMR and the ratio between the 
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two taken. Compounds 6 and 7 were tested as their protonated TFA salts. Carbohydrate 
numbering nomenclature in pyranoside systems follows Figure S1 below. 
 
Figure S1. Nomenclature for numbering of pyranoside systems 
Mass spectra were obtained by the University of Bristol mass spectrometry service by 
electrospray ionisation (ESI) or matrix assisted laser desorption ionisation (MALDI) modes. 
Reactions followed by MALDI were analysed using an Applied Biosystems 4700 Proteomics 
analyser time-of-flight/time-of-flight mass spectrometer. Infra-red spectra were recorded in 
the range 4000-650 cm-1 on a Perkin Elmer Spectrum either as neat films or solids 
compressed onto a diamond window. Optical rotations were measured on a Bellingham + 
Stanley ADP220 polarimeter. The units of the specific rotation, (deg·mL)/g·dm) are implicit 
and are not included with the reported value. Concentration c is given in g/100 mL.  
Analytical high performance liquid chromatography (HPLC) was performed on a Waters 
system with a Waters 2707 Autosampler, a Waters 2535 Quaternary Gradient Module, a 
Waters In-Line Degasser, a Waters Temperature Control Module II, a Waters 2424 ELS 
Detector and a Waters 2998 Photodiode Array Detector (PDA) set to monitor 210 – 450 nm. 
Compound purity was assessed by monitoring the PDA at the wavelength specified, using the 
conditions as follows: The analytical column used was a Phenomenex Luna 3 µm C18(2) 100 
Å (250 × 4.6 mm). For the analytical method, the flow rate was 0.75 mL / min and the mobile 
phases used were 0.05 % formic acid in water for the aqueous phase and 0.05 % formic acid 
in methanol for the organic phase. The gradient was 5 % organic phase for 5 minutes at the 
start before increasing to 40 % organic phase over 25 minutes, then increasing to 95 % 
organic phase over 1 minute before holding at 95 % for 9 minutes. 
Analytical Liquid Chromatography-Mass Spectrometry (LC-MS) was performed on a Waters 
Acquity Ultra Performance LC-MS with PDA detector, set to monitor 100-1600 m/z on the 
MS and 210 – 450 nm on the PDA. The column used was a Waters Acquity UPLC HSS T3 
1.8 µm (2.1 × 50 mm). For the method, the flow rate was 1 mL / min, the mobile phases used 
were 0.05 % formic acid and 0.05 % ammonium acetate in water for the aqueous phase and 
0.04 % formic acid in acetonitrile for the organic phase. The gradient was from 5 % organic 
phase at the start to 98 % organic phase over 9.4 minutes, then holding at 98 % organic for 
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0.4 minutes before returning to 5 % organic over 0.1 minutes and holding at 5 % organic for 
0.3 minutes. 
Preparative HPLC was performed on a Grace Discovery Sciences Reveleris Prep System with 
a Phenomenex Luna 5 µm C18(2) 100 Å AXIA packed (250 × 21.2 mm) column. For 
purification, the instrument was set to monitor the ELSD signal as well as 220 nm, 254 nm 
and 280 nm light on the UV detector. Flow rates were 14 mL / min. The mobile phases used 
were 0.05 % formic acid in water for the aqueous phase and 0.05 % formic acid in methanol 
for the organic phase. The gradient was from 5 % organic phase for 5 minutes at the start to 
40 % organic phase over 10 minutes, then holding at 40 % organic phase for 10 minutes 
before rising to 80 % organic phase over 10 minutes, with 10 minutes at 100 % organic phase 
followed by 5 minutes at 5 % organic phase. The fractions were combined and concentrated 
in the same manner as for FCC. 
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FRET Melting Assays 
FRET melting assays were performed according to the procedure reported by De Cian  and 
co-workers3 on a Stratagene MX3005P qPCR. The oligonucleotides used were: 
 
 
Quadruplex Model Sequence 
F21T (Human Telomeric G-quadruplex) 5’-FAM-GGGTTAGGGTTAGGGTTAGGG-
TAMRA-3’ 
FMycT (c-Myc Pu27 promoter quadruplex) 5’-FAM-TTGAGGGTGGGTAGGGTGGGTAA-
TAMRA-3’ 
F10T (Duplex DNA) 5’-FAM-TATAGCTATA-HEG-TATAGCTATA-
TAMRA-3’  
ds26 (unlabelled competitor duplex DNA) 5'-CAATCGGATCGAATTCGATCCGATTG-3' 
Where FAM = 6-carboxyfluorescein, TAMRA = 6-carboxy-tetramethylrhodamine and HEG = [(-
CH2CH2O-)6] 
All ligands were annealed before use by heating for 2 minutes at 90°C and then placed 
immediately into ice. The final concentration of oligonucleotide was 200nM in all cases, 
except for ds26 which was used in 0.2 µM, 1 µM and 10 µM concentrations as part of the 
FRET competition assay as stated. The buffer used depended on the sequence in question, for 
F21T in Na+ conditions, the final buffer concentration was 100mm NaCl, and 10 mm Li 
Cacodylate. For FMycT (K+ Conditions), 1 mM KCl, 99 mM LiCl and 10 mM Li Cacodylate 
was used. For F21T in K+ conditions as well as for F10T, 10 mM KCl, 90 mM LiCl and 10 
mM Li Cacodylate was used. Ligand concentrations were either 1 µM, 2 µM, 5 µM or 10 
µM. FRET competition assays used the same buffer as their non-competition counterparts, 
and the ratio of quadruplex/duplex DNA was taken as the ratio of G-quartets to nucleotide 
base pairs. Each sample was tested in duplicate, and each experiment was tested in at least 
triplicate to assess the reproducibility of all results. Appropriate control experiments were 
also carried out for each sample set, using the ligand TmPyP4 as a positive control. Data 
processing was carried out using Origin 9, with ΔTmax used to represent ΔTm. 
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Table S1. DNA Stabilization of Ligands in FRET Melting Assay at 10µM Concentration 
(∆Tmax °C). 
Compound F21T K+ F21T Na+ F-myc-T F10T 
1 0.4 ± 0.3 -0.5 ± 0.3 -0.1 ± 0.4 0.0 ± 0.1 
2 14.1 ± 0.5 -1.5 ± 0.1 8.0 ± 0.8 1.8 ± 0.1 
3 19.9 ± 0.4 -1.3 ± 0.4 10.5 ± 0.9 3.2 ± 0.0 
4 8.2 ± 0.6 0.1 ± 0.9 8.3 ± 0.8 2.0 ± 0.1 
5 14.7 ± 0.4 1.0 ± 0.4 14.4 ± 0.9 4.1 ± 0.3 
6 19.9 ± 0.3 1.3 ± 0.2 12.8 ± 1.0 3.2 ± 0.0 
7 13.2 ± 0.4 0.9 ± 0.3 16.1 ± 0.4 5.7 ± 0.2 
 
Table S2. DNA Stabilization of Ligands in FRET Melting Assay at 5µM Concentration 
(∆Tmax °C). 
Compound F21T K+ F21T Na+ F-myc-T F10T 
1 -0.4 ± 0.6 -0.6 ± 0.4 0.9 ± 0.4 0 ± 0.1 
2 9.3 ± 0.6 -1.3 ± 0.5 4.8 ± 0.5 0.9 ± 0.2 
3 13.5 ± 0.7 -2.4 ± 0.1 5.8 ± 0.7 1.7 ± 0.2 
4 4.0 ± 0.6 -0.4 ± 0.8 3.9 ± 0.5 1.0 ± 0.2 
5 10.5 ± 0.7 -1.8 ± 0.5 10.1 ± 0.7 2.3 ± 0.2 
6 13.9 ± 0.7 -2.5 ± 0.3 6.6 ± 0.6 1.4 ± 0.2 
7 8.8 ± 0.5 -0.9 ± 0.4 12.7 ± 0.4 3.5 ± 0.2 
 
Table S3. DNA Stabilization of Ligands in FRET Melting Assay at 2µM Concentration 
(∆Tmax °C). 
Compound F21T K+ F21T Na+ F-myc-T F10T 
1 -0.4 ± 0.4 -0.8 ± 0.7 -0.1 ± 0.2 0.1 ± 0.1 
2 5.1 ± 0.4 -1.0 ± 0.5 1.3 ± 0.8 0 ± 0.1 
3 13.2 ± 0.3 -0.8 ± 0.4 2.0 ± 0.6 0.7 ± 0.2 
4 1.6 ± 0.5 0 ± 0.6 1.5 ± 0.3 0.2 ± 0.3 
5 6.1 ± 0.5 -1.7 ± 0.5 5.0 ± 0.4 0.9 ± 0.1 
6 12.8 ± 0.35 -2.6 ± 0.4 2.7 ± 0.9 0.7 ± 0.2 
7 4.1 ± 0.7 -1.8 ± 0.6 7.3 ± 0.4 2.1 ± 0.1 
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Table S4. Ligand Stabilization of F21T K+ DNA in FRET Competition Assay at 5µM 
Concentration with amount of ds26 added below (∆Tmax °C). 
Compound 0 µM [ds26] 0.2 µM [ds26] 1 µM [ds26] 10 µM [ds26] 
1 - - - - 
2 9.3 ± 0.6 9.9 ± 0.5 9.5 ± 0.7 5.9 ± 0.3 
3 13.5 ± 0.6 13.0 ± 0.5 12.6 ± 0.3 7.6 ± 0.4 
4 4.0 ± 0.6 5 ± 0.3 4 ± 0.5 1.1 ± 0.3 
5 10.5 ± 0.7 10.3 ± 0.8 9.5 ± 0.8 4.1 ± 0.5 
6 13.9 ± 0.7 13.2 ± 0.8 12.3 ± 0.6 7.2 ± 0.3 
7 - - - - 
 
Table S5. Ligand Stabilization of F21T K+ DNA in FRET Competition Assay at 1µM 
Concentration with amount of ds26 added below (∆Tmax °C). 
Compound 0 µM [ds26] 0.2 µM [ds26] 1 µM [ds26] 10 µM [ds26] 
1 - - - - 
2 - - - - 
3 10.1 ± 0.3 4.5 ± 0.5 3.9 ± 0.4 1.9 ± 0.4 
4 - - - - 
5 3.7 ± 0.3 2.5 ± 0.5 2.3 ± 0.4 0.4 ± 0.7 
6 9.8 ± 0.6 1.3 ± 0.3 1.1 ± 0.3 -0.6 ± 0.6 
7 - - - - 
TmPyP4 27.4 ± 0.4 17.8 ± 0.4 14.4 ± 0.6 8.7 ± 0.6 
 
Table S6. Ligand Stabilization of F-Myc-T DNA in FRET Competition Assay at 5µM 
Concentration with amount of ds26 added below (∆Tmax °C). 
Compound 0 µM [ds26] 0.2 µM [ds26] 1 µM [ds26] 10 µM [ds26] 
1 - - - - 
2 4.8 ± 0.5 3.4 ± 0.3 3.9 ± 0.3 0.5 ± 0.4 
3 5.8 ± 0.7 5.7 ± 0.2 5.0 ± 0.2 1.6 ± 0.3 
4 3.9 ± 0.5 3.9 ± 0.2 2.8 ± 0.2 -0.3 ± 0.3 
5 10.1 ± 0.7 9.7 ± 0.2 9.0 ± 0.4 2.2 ± 0.3 
6 6.6 ± 0.6 8.4 ± 0.5 7.2 ± 0.4 2.4 ± 0.1 
7 - - - - 
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Figure S2. FRET Competition Assay of F21T K+ at 25:1 (ligand:quadruplex) ratio, with 
unlabelled ds26 duplex DNA added as a competitor.  
 
Figure S3. FRET Competition Assay of F21T K+ at 5:1 (ligand:quadruplex) ratio, with 
unlabelled ds26 duplex DNA added as a competitor. Note that at very low quadruplex / 
duplex DNA ratios, 3 is comparable with TmPyP4, while 6 is failing. This emphasises the 
importance of carbohydrates on increasing specific binding to the K+ form of the human 
telomeric G-quadruplex. 
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Figure S4. FRET Competition Assay of F-Myc-T at 25:1 (ligand:quadruplex) ratio, with 
unlabelled ds26 duplex DNA added as a competitor. 
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Circular Dichroism 
Circular Dichroism (CD) titrations were recorded using a Jasco J-810 spectrometer fitted with 
a Peltier temperature controller. Measurements were taken in a quartz cuvette with a path 
length of 5 mm, at 20°C, at a 50 nm / min scanning speed at 1 nm intervals, with a 1 nm 
bandwidth. The CD spectrum was recorded between 450 and 200 nm, and baseline corrected 
for the buffer used. The oligonucleotide sequence used was: 
telo23 (human telomeric G-quadruplex): 5'-TAGGGTTAGGGTTAGGGTTAGGG -3' 
The oligonucleotide was at a concentration of 4.22 µM which gave an OD of 1 and the buffer 
used was either sodium or potassium phosphate (100 mM, pH 7.4). Oligonucleotide 
concentration remained constant throughout, and dilutions were made using a solution 
containing both oligonucleotide and the ligand, with the amount added determining the 
relative ratio of the two species. The reported spectrum for each sample represents the 
average of 3 scans and is baseline corrected for the buffer and ligand. Data processing was 
carried out using Prism 6 with a 4 point second order smoothing polynomial applied to all 
spectra. Observed ellipticities were converted to mean residue ellipticity (θ) = deg x cm2 x 
dmol-1 (mol ellip). 
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Figure S5. CD titration of 3 with telo23 in Na+ buffer. The increase in ligand concentration 
corresponds to a shift towards a mixture of antiparallel and hybrid type topologies (increase 
in negative band at 265nm and increase / shift in positive band at 295 nm). 
 
Figure S6. CD titration of 5 with telo23 in K+ buffer. The increase in ligand concentration 
corresponds to an increase in hybrid-type topology, similar to 3 but to a lesser extent. 
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Figure S7. CD titration of 5 with telo23 in Na+ buffer. The increase in ligand concentration 
corresponds to a shift towards a mixture of antiparallel and hybrid type topologies (increase 
in negative band at 265nm and increase / shift in positive band at 295 nm). 
 
Figure S8. CD titration of 6 with telo23 in K+ buffer. The increase in ligand concentration 
corresponds to an increase in hybrid-type topology, similar to 3 but to a lesser extent. 
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Figure S9. CD titration of 6 with telo23 in Na+ buffer. The increase in ligand concentration 
corresponds to a shift towards a mixture of antiparallel and hybrid type topologies (increase 
in negative band at 265nm and increase / shift in positive band at 295 nm). 
Figure S10. CD titration of 3 with telo23 without buffer (no preformed G-quadruplex). These 
results suggest the induction of a hybrid-type G-quadruplex topology of the oligonucleotide 
upon the addition of compound 3. 
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Isothermal Titration Calorimetry (ITC) 
ITC measurements were carried out in a MicroCal Auto-iTC200 titration calorimeter 
(MicroCal, Northampton, MA).All ITC experiments were carried out in the same buffer (100 
mM potassium phosphate, pH 7.4). The oligonucleotide sequence used was: 
telo23 (human telomeric G-quadruplex): 5'-TAGGGTTAGGGTTAGGGTTAGGG -3' 
The volume of sample in the reference cell was always 200 µL, and the volume of sample in 
the syringe was always 40 µL. Before loading, all solutions were thoroughly degassed. The 
reference cell was filled with the degassed buffer. The oligonucleotide was annealed and 
placed in the sample cell (15 µM), and the respective ligand was dissolved in the same buffer 
and placed in the syringe (300 µM). 19 injections were made at 25°C, at 10 µcal/sec with an 
initial delay of 60 seconds. The stirring speed was 750 rpm throughout. The first injection 
was 0.4 µL for a duration of 0.8 seconds, the next injections were 2 µL for a duration of 4 
seconds. The spacing between each injection was 150 seconds, and the filter period was 5 
seconds. The heats of dilution were determined by parallel experiments by injecting the 
respective ligand into the same buffer. Each experiment was performed in duplicate to assess 
the reproducibility of the result.. 
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The thermograms (integrated heat / injection data) obtained were processed according to the 
procedure outlined by Brautigam et. al.4 This consisted of a bias-free, global analysis using 
freely available NITPIC,5 SEDPHAT6 and GUSSI7 software. Firstly, the thermograms 
imported and  were integrated automatically using NITPIC. The results were imported into 
SEDPHAT and underwent a global analysis and curve-fitting. Multiple different non-linear 
regression binding models were trialled, and the simplest binding model that was capable of 
rationalising the data was selected. In this case, all data was fitted to the ‘A+B <-> AB 
heterogeneous association’ model. The association constant (Ka) and enthalpy change (ΔH), 
were minimised simultaneously and fitted to all datasets as part of the curve fitting process 
until a minimum was found. These values were then used to calculate the entropy change 
(ΔS) and Gibbs free energy (ΔG) using the equation ΔG = -RTLn Ka = ΔH-TΔS where R is 
the gas constant and T is the absolute temperature. Finally, this data was imported into 
GUSSI to generate the final figures. Error was calculated using the ‘automatic confidence 
interval search with projection method’ and used a P value of 0.683. The stoichiometry (N) 
was calculated by using the ‘one-set of sites’ binding model in the Microcal Analysis add-on 
for Origin 9.0 
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Figure S11. ITC Thermogram and nonlinear regression best fit for the binding of 3 to telo23. 
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Figure S12. ITC Thermogram and nonlinear regression best fit for the binding of 5 to telo23. 
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Figure S13. ITC Thermogram and nonlinear regression best fit for the binding of 6 to telo23. 
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Molecular Docking Studies 
Molecular docking studies were performed using Molsoft ICM-Pro (Molsoft L.L.C., San 
Diago, CA)8 The crystal structure of the tetrasubstituted naphthalene diimide ligand MM41 
bound to a human telomeric DNA G-quadruplex 21-mer (PDB 4DA3)9 was used as an initial 
modelling template to probe the binding modes of compounds 2-7 to the parallel K+ human 
telomeric G-quadruplex. Subsequent DNA structures that were modelled include: the anti-
parallel Na+ human telomeric G-quadruplex with a ligand bound to the top face (2MCO)10, 
the anti-parallel Na+ human telomeric G-quadruplex with a ligand bound to the bottom face 
(2MCC)10, the 3+1 hybrid human telomeric G-quadruplex (2MB3)11 and the Pu27T parallel 
c-Myc promoter G-quadruplex (2MGN)12. Before docking, the G-quadruplex structure was 
converted to an ICM object, and the original ligand was removed. All atom types, hydrogen 
and missing heavy atoms were added to the receptor structure. According to the ICM local 
energy minimization method, the molecular conformation was represented by the internal 
coordinate variables. Energy calculations were based on a modified version of the ECEPP/3 
force field with a distance-dependent dielectric function. Docking was conducted by a biased 
probability Monte Carlo (BPMC) minimization procedure. During the docking stimulation, 
grid energy, continuum electrostatic and entropy terms were used to evaluate the binding 
energy of ligands 1-7 with the DNA structure and the internal conformational energy of the 
ligand in order to find the most favourable orientation. Each independent docking was 
repeated 3 times, and the binding energies were computed. 
Table S7. Predicted ICM-VLS scores for ligands X-Y. The lower the VLS score, the stronger 
the interaction is predicted to be. This score does not take into account ligand strain, which is 
reported below. 
Compound Parallel 
hTel G4 
(4DA3) 
Antiparallel 
hTel G4, 
top face 
(2MCO) 
Antiparallel 
hTel G4, 
bottom face 
(2MCC) 
3+1 Hybrid 
htel G4 
(2MB3) 
Pu24T, 
parallel c-Myc 
promoter G4 
(2MGN) 
1 -13.61 - - - - 
2 -29.22 - - -21.59 -26.59 
3 -15.92 - - -30.55 -39.22 
4 -24.11 - - -28.31 -28.77 
5 -26.16 - - -23.33 -31.34 
6 -23.60 -31.82 -26.44 -17.02 -29.88 
7 -17.61 - - -22.11 - 
PDB IDs for the structures used are reported in brackets. 
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Table S8. Predicted ICM-Ligand Strain scores for ligands X-Y. The lower the Ligand Strain 
score, the less strained the ligand. 
Compound Parallel 
hTel G4 
(4DA3) 
Antiparallel 
hTel G4, 
top face 
(2MCO) 
Antiparallel 
hTel G4, 
bottom face 
(2MCC) 
3+1 Hybrid 
htel G4 
(2MB3) 
Pu24T, 
parallel c-Myc 
promoter G4 
(2MGN) 
1 8.25 - - - - 
2 12.4 - - 9.56 18.33 
3 11.67 - - 12.77 9.74 
4 5.24 - - 7.45 5.20 
5 5.49 - - 4.87 5.43 
6 6.63 7.91 11.71 6.03 6.36 
7 4.97 - - 4.08 - 
PDB IDs for the structures used are reported in brackets. 
 
 
 
Table S 9. Predicted ICM-Scores for ligands X-Y. This score is an overall score, which takes 
into account both the interaction energy (VLS-Score) and the ligand strain (Ligand Strain 
Score). The lower the overall score, the better the predicted interaction overall. 
Compound Parallel 
hTel G4 
(4DA3) 
Antiparallel 
hTel G4, 
top face 
(2MCO) 
Antiparallel 
hTel G4, 
bottom face 
(2MCC) 
3+1 Hybrid 
htel G4 
(2MB3) 
Pu24T, 
parallel c-Myc 
promoter G4 
(2MGN) 
1 -5.37 - - - - 
2 -16.82 - - -12.03 -8.26 
3 -4.25 - - -17.78 -29.48 
4 -18.87 - - -20.87 -23.57 
5 -20.66 - - -18.47 -25.9 
6 -16.97 -23.90 -14.72 -10.99 -23.53 
7 -12.64 - - -18.03 - 
PDB IDs for the structures used are reported in brackets. 
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Figure S14. Modelled structure of compound 3 bound to the parallel K+ human telomeric G-
quadruplex. Note the hydrogen bonding interaction of the C-2 hydroxyl with the phosphate in 
the groove (2.11Å distance) and the electrostatic interaction of the imidazolium group with 
another phosphate in the groove of the quadruplex. 
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Figure S15. Modelled structure of compound 6 bound to the parallel K+ human telomeric G-
quadruplex. Note the hydrogen bonding interaction of the terminal amine with the phosphate 
in the groove of the quadruplex (2.92Å distance). 
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Figure S16. Side view of compound 1 docked into the parallel K+ human telomeric G-
quadruplex. Note the two intramolecular hydrogen bonding interactions on the ligand 
between C-4 and C-6 hydroxyls (2.00Å distance) on one side and C-2 and an NDI C=O on 
the other side (1.94Å distance). 
 
 
Figure S17. Top view of compound 1 docked into the parallel K+ human telomeric G-
quadruplex. Note the two intramolecular hydrogen bonding interactions on the ligand 
between C-4 and C-6 hydroxyls (2.00Å distance) on one side and C-2 and an NDI C=O on 
the other side (1.94Å distance). 
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Figure S18. Side view of compound 2 docked into the parallel K+ human telomeric G-
quadruplex. Note the two hydrogen bonding interactions at C-1 (1.96Å distance) and C-4 
(1.95Å distance). 
 
Figure S19. Top view of compound 2 docked into the parallel K+ human telomeric G-
quadruplex. Note the two hydrogen bonding interactions at C-1 (1.96Å distance) and C-4 
(1.95Å distance). 
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Figure S20. Side view of compound 3 docked into the parallel K+ human telomeric G-
quadruplex. Note the hydrogen bonding interaction at C-2 (2.11Å distance). 
 
Figure S21. Top view of compound 3 docked into the parallel K+ human telomeric G-
quadruplex. Note the hydrogen bonding interaction at C-2 (2.11Å distance). 
S27 
 
 
Figure S22. Side view of compound 4 docked into the parallel K+ human telomeric G-
quadruplex. 
 
Figure S23. Top view of compound 4 docked into the parallel K+ human telomeric G-
quadruplex. 
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Figure S24. Side view of compound 5 docked into the parallel K+ human telomeric G-
quadruplex. 
 
Figure S25. Top view of compound 5 docked into the parallel K+ human telomeric G-
quadruplex. 
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Figure S26. Side view of compound 6 docked into the parallel K+ human telomeric G-
quadruplex. 
  
Figure S27. Top view of compound 6 docked into the parallel K+ human telomeric G-
quadruplex. 
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Figure S28. Side view of compound 7 docked into the parallel K+ human telomeric G-
quadruplex. 
 
Figure S29. Top view of compound 7 docked into the parallel K+ human telomeric G-
quadruplex. 
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Figure S30. Side view of compound 3 docked into the 3+1 hybrid K+ human telomeric G-
quadruplex. Note the hydrogen bonding interactions between the C-2 hydroxyl and a guanine 
NH2 on one side (1.94Å distance) and C-3 hydroxyl and a ribose oxygen on the other side 
(2.29Å distance) (circled). 
 
Figure S31. Top view of compound 3 docked into the 3+1 hybrid K+ human telomeric G-
quadruplex. Note the hydrogen bonding interactions between the C-2 hydroxyl and a guanine 
NH2 on one side (1.94Å distance) and the C-3 hydroxyl and a ribose oxygen on the other side 
(2.29Å distance) (circled). 
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Figure S32. Side view of compound 6 docked into the 3+1 hybrid K+ human telomeric G-
quadruplex. 
 
Figure S33. Top view of compound 6 docked into the 3+1 hybrid K+ human telomeric G-
quadruplex. 
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Figure S34. Side view of compound 3 docked into the Pu27T c-Myc parallel G-quadruplex. 
Note the hydrogen bonding interactions between the C-4 hydroxyl and a phosphate on one 
side (2.39Å distance), and the C-2 & C-3 hydroxyls and two phosphates on the other side 
(2.25Å & 2.33Å distance respectively) (circled). 
 
Figure S35. Top view of compound 3 docked into the Pu27T c-Myc parallel G-quadruplex. 
Note the hydrogen bonding interactions between the C-4 hydroxyl and a phosphate on one 
side (2.39Å distance), and the C-2 & C-3 hydroxyls and two phosphates on the other side 
(2.25Å & 2.33Å distance respectively) (circled). 
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Figure S36. Side view of compound 6 docked into the Pu27T c-Myc parallel G-quadruplex. 
 
Figure S37. Top view of compound 6 docked into the Pu27T c-Myc parallel G-quadruplex. 
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Figure S38. Side view of compound 6 docked into the top face of the antiparallel Na+ human 
telomeric G-quadruplex. Note the hydrogen bonding interaction with a phosphate 
(2.24Å distance). 
 
Figure S 39. Top view of compound 6 docked into the top face of the antiparallel Na+ human 
telomeric G-quadruplex. 
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Figure S40. Side view of compound 6 docked into the top face of the antiparallel Na+ human 
telomeric G-quadruplex. 
 
Figure S41. Top view of compound 6 docked into the top face of the antiparallel Na+ human 
telomeric G-quadruplex. 
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Cell Culture Protocols 
WI-38 (Caucasian fibroblast-like fetal lung cells) and MCF7 (Human breast adenocarcinoma 
cell line) were grown in Minimal Essential Medium (MEM), HeLa (Human cervical 
carcinoma cell line) and MDA (Human breast adenocarcinoma) were grown in Dulbecco’s 
Minimal Essential Medium (DMEM). All growth media were supplemented with antibiotic-
antimycotic (Anti-Anti) and 10-20 % fetal bovine serum (FBS). Confluent cultures were 
detached from the surface using trypsin (Tryp LE Express) and plated at 2*104 cells/well in 
96-well plates. Cell culture media and additives were purchased from Invitrogen, Life 
Technologies. 
Toxicity Assays 
The influence of compounds 1 - 7 and Doxorubicin on cell survival after exposure to the 
compounds was quantified by measuring calcein fluorescence. The fluorescence, retained 
within live cells only, results from activity of esterases on the (nonfluorescent) calcein AM 
(Molecular Probes). Changes in cell metabolism were assessed using AlamarBlue (AB, Life 
Technologies), a cytosolic substrate for reductive metabolism (resazurin to resorufin) whose 
fluorescence spectrum changes on reduction by cytosolic enzymes. WI-38 (fetal lung cells), 
HeLa (human cervical carcinoma) MDA (human breast adenocarcinoma) and MCF7 (human 
breast adenocarcinoma) were incubated with 0-100 µM of compounds 1 - 7 and Doxorubicin 
for 72 hours. Each experiment was repeated at least twice, in medium with reduced FBS 
(5%), with each data point conducted in octuplicate. After 72h the plates were washed with 
PBS, and AB (5 % solution), calcein (5 µM) and sytox (0.1 µM) were added in medium 
without FBS. After 1 hour incubation, the fluorescence of all three dyes was read using a 
plate reader (BMG Labtech CLARIOstar) (AB λex = 545 nm  λem =  590 nm, calcein λex = 
494 nm, λem =  517 nm, sytox red λex = 633 nm  λem =  660 nm). Results are expressed as 
percentages of control, versus the logarithm of the ligand concentration. Curves were fitted to 
determine the absolute IC50s using the non-linear regression function of GraphPad Prism 6, 
using the ‘log(inhibitor) vs. normalized response – variable slope’ or ‘log(inhibitor) vs 
response – variable slope’ equations as appropriate (Table 3 and Table S10). 
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Table S10. Cytotoxicity of compounds 1-7 and doxorubicin determined by 72h Alamar 
Blue Assay (measure of reductive metabolism).a 
 
Cell Line WI-38 HeLa MCF7 MDA 
Doxorubicin 0.20      
(0.17, 0.22) 
0.40 
(0.35,0.45) 
0.79 
(0.76,0.85) 
1.30 
(1.05,1.61) 
1 >100 >100 >100 >100 
2 >100 >100 >100 >100 
3 ~100 >100 >100 >100 
4 22.9 
(19.94,26.30) 
0.30 
(0.29,0.32) 
12.97 
(11.83,14.21) 
42.63 
(35.98,50.50) 
5 19.03 
(14.58,24.84) 
0.15  
(0.14,0.16) 
3.35 
(3.19,3.52) 
55.22 
(40.61,75.10) 
6 1.02     
(0.94,1.11) 
0.50 
(0.44,0.57) 
3.00 
(2.66,3.38) 
0.45 
(0.38,0.54) 
7 0.99 
(0.92,1.06) 
0.34 
(0.32,0.36) 
0.71 
(0.68,0.75) 
0.18 
(0.17,0.19) 
a Absolute IC50 values measured in µM, with 95% confidence interval in brackets. 
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Figure S42. Calcein Assay data for WI-38 with doxorubicin and 1-7. The very small (below 
assay sensitivity) number of cells surviving at high concentration of Doxorubicin, 6 and 7 
invalidates metabolism/cell calculations.
Figure S43. Effects on reductive metabolism (Alamar Blue Assay) for WI-38 after 72h 
incubation with doxorubicin and 1-7. 
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Figure S44. Calcein Assay data for HeLa with doxorubicin and 1-7. The very small (below 
assay sensitivity) number of cells surviving at high concentration of Doxorubicin, 6 and 7 
invalidates metabolism/cell calculations. 
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Figure S45. Effects on reductive metabolism (Alamar Blue Assay) for HeLa after 72h 
incubation with doxorubicin and 1-7. 
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Figure S46. Calcein Assay data for MCF7 with doxorubicin and 1-7. The very small (below 
assay sensitivity) number of cells surviving at high concentration of Doxorubicin, 6 and 7 
invalidates metabolism/cell calculations.
Figure S47. Effects on reductive metabolism (Alamar Blue Assay) for MCF7 after 72h 
incubation with doxorubicin and 1-7. 
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Figure S48. Calcein Assay data for MDA with doxorubicin and 1-7. 1, 4 and 5 appear to 
have a non-monotonic dose-response relationship. The very small (below assay sensitivity) 
number of cells surviving at high concentration of Doxorubicin, 6 and 7 invalidates 
metabolism/cell calculations. 
 Figure S49. Effects on reductive metabolism (Alamar Blue Assay) for MDA after 72h 
incubation with doxorubicin and 1-7. 
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Confocal Microscopy 
Confocal Microscopy was carried out by the Wolfson Bioimaging Facility at the University 
of Bristol on a Lecia SP8  AOBS confocal laser scanning microscope attached to a Lecia DM 
I6000 inverted epifluorescence microscope with ‘Adaptive Focus Control’ to correct focus 
drift during time-courses (BBSRC Alert 13 capital grant (BB/L014181/1). All images were 
taken at 37 °C using the HeLa cell line. Cells were incubated with the 100 µM of the 
compound for testing at either 16h or 30min before being washed with PBS, and imaged in 
imaging medium. Bright-field images were taken using Transmitted Light Microscopy using 
a 63x 1.4 oil submersion lens. For the fluorescence images, the 405 nm diode laser was used 
for excitation and the emission at 535 nm was monitored. The images were analysed by Fiji 
software (ImageJ). 
 
Figure S50. Bright-field transmitted light microscopy images of cells visualised in 
fluorescence confocal microscopy. Top left: Control; (1) 6 after 30 min exposure at 100 µM; 
(2) 3 after 30 min exposure at 100 µM; (3) 3 after 16h exposure at 100 µM. 
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Figure S51. Overlay of bright-field transmitted light microscopy images and fluorescence 
confocal microscopy of cells visualised. Top left: Control; (1) 6 after 30 min exposure at 100 
µM; (2) 3 after 30 min exposure at 100 µM; (3) 3 after 16h exposure at 100 µM. 
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Figure S52. Fluorescence confocal microscopy images of cells visualised, monitoring the 
emission at 545 nm. Top left: Control; (1) 6 after 30 min exposure at 100 µM; (2) 3 after 30 
min exposure at 100 µM; (3) 3 after 16h exposure at 100 µM. 
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Experimental Procedures and Data 
2-azidoethyl methanesulfonate (S1) 
 
To a solution of 2-azidoethanol13 (200 mg, 2.30 mmol) in THF (20 mL) and triethylamine 
(3.2 mL, 22.98 mmol) was added mesyl chloride (890 µL, 11.49 mmol) at 0 °C, and the 
mixture was allowed to warm to room temperature. Stirring continued for 3 h, until the 
reaction was determined to be complete by TLC. CH2Cl2 (50 mL) and saturated sodium 
bicarbonate (50 mL) were added, and the two layers were separated. The organic layer was 
washed with sodium bicarbonate (2 × 50 mL) and saturated brine (45 mL) and dried over 
MgSO4. The Solvent was removed in vacuo to yield the crude product as a colorless oil (323 
mg) which was used without further purification. 1H NMR (400 MHz, CDCl3) δ 4.34 (2H, t, 
J = 5.0 Hz, OCH2CH2), 3.59 (2H, t, J = 5.0 Hz, N3CH2CH2), 3.07 (3H, s, SO2CH3); 13C 
NMR (101 MHz, CDCl3) δ 67.7 (OCH2CH2), 49.9 (N3CH2CH2), 37.8 (SO2CH3). Proton and 
carbon NMR were consistent with literature data.14 
3-azidopropyl methanesulfonate (S2) 
 
To a solution of 3-azido-1-propanol15 (205 mg, 2.03 mmol) in THF (20 mL) and 
triethylamine (2.8 mL, 19.78 mmol) was added mesyl chloride (765 µL, 9.89 mmol) at 0 °C, 
and the mixture was allowed to warm to room temperature. Stirring continued for 3 h, until 
the reaction was determined to be complete by TLC. CH2Cl2 (50 mL) and saturated sodium 
bicarbonate (50 mL) were added, and the two layers were separated. The organic layer was 
washed with sodium bicarbonate (2 × 50 mL) and saturated brine (45 mL) and dried over 
MgSO4. The Solvent was removed in vacuo  to yield the crude product as a colorless oil (373 
mg) which was used without further purification. 1H NMR (400 MHz, CDCl3) δ 4.32 (2H, t, 
J = 6.0 Hz, OCH2CH2), 3.49 (2H, t, J = 6.4 Hz, NCH2CH2), 3.03 (3H, s, SO2CH3), 2.01 (2H, 
p, J = 6.2 Hz, CH2CH2CH2); 13C NMR (101 MHz, CDCl3) δ 66.5 (OCH2CH2), 47.3 
(N3CH2CH2), 37.4 (SO2CH3), 28.7 (CH2CH2CH2). Proton and carbon NMR were consistent 
with literature data.16  
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1-(2-azidoethyl)-3-methyl-1H-imidazol-3-ium methanesulfonate (S3) 
 
To a solution of 2-azidoethyl methanesulfonate (323 mg, 1.96 mmol) and KBF4 (487 mg, 
3.87 mmol) in acetonitrile (20 mL) was added 1-methylimidazole (500 µL, 6.27 mmol). The 
reaction mixture was heated to 100 °C for 24 h until the reaction was determined to be 
complete by TLC. After cooling to room temperature, the reaction mixture was filtered and 
concentrated under reduced pressure, dried under high vacuum and washed three times with a 
1:1 hexane / diethyl ether (10 mL) mixture with sonication. After decantation, the solvent was 
removed in vacuo to yield the product as a colourless solid (203 mg, 42 %). 1H NMR (400 
MHz, CD3OD) δ 8.90 (1H, s, NCHN), 7.64 (1H, t, J = 1.8 Hz, NCHCHN), 7.58 (1H, t, J = 
1.8 Hz, NCHCHN), 4.37 (2H, t, J = 5.6 Hz, N3CH2CH2), 3.95 (3H, s, NCH3), 3.84 (2H, t, J = 
5.6 Hz, NCH2CH2N3) 3.82 (3H, s, SO2CH3); 13C NMR (126 MHz, CD3OD) δ 138.4 (NCN), 
125.0 (NCHCHN), 123.9 (NCHCHN), 51.5 (NCH2CH2N3), 49.9 (N3CH2CH2), 36.5 (NCH3) 
34.7 (SO2CH3); ESI-HRMS for C6H10N5+ (M+) calcd: 152.0931; found: 152.0935; νmax / cm-
1 (film): 3632, 3162, 3123, 2105, 1578, 1452, 1351, 1287, 1169, 1030, 840, 753. 
1-(3-azidopropyl)-3-methyl-1H-imidazol-3-ium methanesulfonate (S4) 
 
To a solution of 3-azidopropyl methanesulfonate (354 mg, 1.98 mmol) and KBF4 (575 mg, 
4.58 mmol) in acetonitrile (20 mL) was added 1-methylimidazole (500 µL, 6.27 mmol). The 
reaction mixture was heated to 100 °C for 16 h until the reaction was determined to be 
complete by TLC. After cooling to room temperature, the reaction mixture was filtered and 
concentrated under reduced pressure, dried under high vacuum and washed three times with a 
1:1 hexane / diethyl ether (10 mL) mixture with sonication. After decantation, the solvent was 
removed in vacuo to yield the product as a colourless solid (309 mg, 62 %). 1H NMR (400 
MHz, CD3OD) δ 8.87 (1H, s, NCHN), 7.62 (1H, t, J = 1.8 Hz, NCHCHN), 7.56 (1H, t, J = 
1.8 Hz, NCHCHN), 4.30 (2H, t, J = 7.1 Hz, N3CH2CH2), 3.93 (3H, s, NCH3), 3.79 (3H, s, 
SO2CH3), 3.44 (2H, t, J = 6.4 Hz, NCH2CH2N3), 2.14 (2H, p, J = 6.7 Hz, CH2CH2CH2); 13C 
NMR (126 MHz, CD3OD) δ 140.7 (NCHN), 127.6 (NCHCHN), 126.2 (NCHCHN), 51.6 
(NCH2CH2N3), 50.7 (N3CH2CH2), 39.0 (NCH3), 37.0 (SO2CH3), 32.8 (CH2CH2CH2); ESI-
HRMS for C7H12N5+ (M+) calcd: 166.1087; found: 166.1081; νmax / cm-1 (film): 3631, 3162, 
2919, 2850, 2101, 1573, 1462, 1285, 1168, 1017, 896, 845, 754. 
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1-(2-aminoethyl)-3-methyl-1H-imidazol-3-ium chloride (S5) 
 
To a solution of compound S3 (48 mg, 0.20 mmol) in acetonitrile (1 mL) and ethanol with 
5% HCl (3 mL) was added palladium catalyst (10% Pd-C, 17 mg) and then the reaction 
mixture was hydrogenated at 1 atm for 1 h until complete consumption of the starting 
material was observed by TLC. The resulting mixture was then filtered through a Celite bed 
and washed with MeOH. The filtrate was concentrated in vacuo to give the final product as a 
yellow oil (32 mg). The product was used in the next step without further purification. 1H 
NMR (400 MHz, CD3OD) δ 9.06 (1H, s, NCHN), 7.73 (app s, NCHCHN), 7.65 (app s, 
NCHCHN), 4.61 (2H, s, CHNCH2), 3.97 (3H, s, NCH3), 3.53 (2H, s, CH2NH2); 13C NMR 
(101 MHz, CD3OD) δ 137.7 (NCHN), 124.3 (NCHCHN), 122.5 (NCHCHN), 46.6 
(CHNCH2), 39.0 (CH2NH2), 35.6 (NCH3).  
1-(3-aminopropyl)-3-methyl-1H-imidazol-3-ium chloride (S6) 
 
To a solution of compound S4 (49 mg, 0.19 mmol) in ethanol with 5% HCl (3 mL) was 
added palladium catalyst (10% Pd-C, 13 mg) and then the reaction mixture was hydrogenated 
at 1 atm for 1 h until complete consumption of the starting material was observed by TLC. 
The resulting mixture was then filtered through a Celite bed and washed with MeOH. The 
filtrate was concentrated in vacuo to give the final product as a yellow oil (34 mg). The 
product was used in the next step without further purification. 1H NMR (400 MHz, D2O) δ 
8.76 (1H, s, NCHN), 7.50 (1H, d, J = 1.6 Hz, NCHCHN), 7.44 (1H, t, J = 1.7 Hz, 
NCHCHN), 4.31 (2h, t, J = 7.3 Hz, CHNCH2), 3.87 (3H, s, NCH3), 3.09 – 2.97 (2H, m, 
NH2CH2), 2.25 (2H, p, J = 7.6 Hz, CH2CH2CH2). 13C NMR (101 MHz, D2O) δ 135.5 
(NCHN), 123.3 (NCHCHN), 121.5 (NCHCHN), 45.8 (CHNCH2), 35.8 (CH2NH2), 35.4 
(NCH3), 26.8 (CH2CH2CH2).  
1-(2-azidoethyl)-6-methanesulfonate-β-D-glucopyranoside (10) 
 
To a stirred solution of 1-(2-azidoethyl)-β-D-glucopyranoside17 (302 mg, 1.21 mmol) in 
anhydrous pyridine (2.5 mL) was added methanesulfonyl chloride (103 µL, 1.34 mmol) at         
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-50°C dropwise over 20 mins. The mixture was kept at -50°C for 2.5 h until complete 
consumption of the starting material was observed by TLC. The reaction mixture was then 
quenched by the addition of MeOH (5 mL) and the solvent was removed in vacuo. The 
resulting residue was purified by column chromatography (95:5 to 8:2 CH2Cl2 / MeOH) to 
yield the product as a colourless solid (212 mg, 53 %). 1H NMR (400 MHz, DMSO-d6) δ 
5.30 (1H, d, J = 5.5 Hz, OH), 5.13 (1H, d, J = 5.1 Hz, OH), 5.10 (1H, d, J = 5.0 Hz, OH), 
4.41 (1H, dd, J = 11.0, 1.9 Hz, H-6a), 4.29 (1H, d, J = 7.8 Hz, H-1), 4.27 (1H, dd, J = 11.1, 
6.0 Hz, H-6b), 3.85 (1H, ddd, J = 11.2, 5.8, 4.2 Hz, OCHHCH2), 3.68 (1H, ddd, J = 10.9, 5.9, 
4.5 Hz, OCHHCH2), 3.48 – 3.42 (3H, m, H-5 & CH2CH2N3), 3.22 – 3.15 (4H, m, H-3 & 
CH3), 3.09 (1H, td, J = 9.2, 5.5 Hz, H-4), 2.99 (1H, ddd, J = 9.0, 7.8, 5.1 Hz, H-2); 13C NMR 
(101 MHz, DMSO-d6) δ 103.3 (C-1), 76.8 (C-3), 73.9 (C-5), 73.6 (C-2), 70.2 (C-6), 69.8 (C-
4), 68.0 (OCH2CH2), 50.8 (N3CH2), 37.2 (SO2CH3); ESI-HRMS for C9H17N3NaO8S+ 
(MNa+) calcd: 350.0629; found: 350.0619; νmax / cm-1 (film): 3417, 2933, 2096, 1349, 1275, 
1169, 1078, 974, 925, 803; [∝]
 = +0.9 (c 1.0, MeOH). 
1-(2-azidoethyl)-6-methanesulfonate-α-D-mannopyranoside (11) 
 
To a stirred solution of 1-(2-azidoethyl)-α-D-mannopyranoside18 (1.28 g, 5.12 mmol) in 
anhydrous pyridine (10 mL) was added methanesulfonyl chloride (436 µL, 5.63 mmol) at            
-40°C dropwise over 20 mins. The mixture was kept at -40°C for 5.5 hours until complete 
consumption of the starting material was observed by TLC. The reaction mixture was then 
quenched by the addition of aq. sat. NaHCO3 (5 mL) and the solvent was removed in vacuo. 
The resulting residue was purified by column chromatography (98:2 to 9:1 CH2Cl2 / MeOH) 
to yield the product as a colourless solid (877 mg, 52 %). 1H NMR (400 MHz, D2O) δ 4.93 
(1H, d, J = 1.7 Hz, H-1), 4.61 (1H, dd, J = 11.4, 2.2 Hz, H-6a), 4.53 (1H, dd, J = 11.4, 5.4 
Hz, H-6b), 4.00 (1H, dd, J = 3.4, 1.8 Hz, H-2), 3.97 – 3.89 (2H, m, H-5 & OCHHCH2), 3.86 
(1H, dd, J = 9.7, 3.4 Hz, H-3), 3.77 – 3.70 (2H, m, H-4 & OCHHCH2), 3.59 – 3.46 (2H, m, 
CH2CH2N3), 3.27 (3H, s, SO2CH3); 13C NMR (101 MHz, D2O) δ 100.0 (C-1), 70.5 (C-5), 
70.2 (C-3), 69.7 (C-2), 69.4 (C-6), 66.5 (OCH2CH2), 66.0 (C-4), 50.1 (N3CH2), 36.5 
(SO2CH3); ESI-HRMS for C9H17N3NaO8S+ (MNa+) calcd: 350.0629; found: 350.0631; νmax / 
cm-1 (film): 3391, 2937, 2106, 1636, 1451, 1414, 1347, 1172, 1135, 1060, 965, 836; [∝]
 = 
+41.0 (c 0.9, MeOH). 
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1-(2-azidoethyl)-6-(3-methyl-1H-imidazol-3-ium)-6-deoxy-β-D-glucopyranoside 
methanesulfonate (12) 
 
To a solution of sugar 10 (35 mg, 0.11 mmol) in acetonitrile (1 mL) and water (0.5 mL) was 
added 1-methylimidazole (50 µL, 0.63 mmol). The reaction mixture was stirred and heated to 
reflux for 48 h until the reaction was determined to be complete by TLC. After cooling to 
room temperature, the reaction mixture was filtered and concentrated in vacuo, dried under 
high vacuum and washed three times with a 1:1 hexane / diethyl ether (10 mL) mixture with 
sonication. After decantation, the oil was dried under vacuum, and purified by column 
chromatography (9:1 CH2Cl2 / MeOH then 65:35:2 CH2Cl2 / MeOH / H2O) to yield the 
product as a colourless solid (28 mg, 62 %). 1H NMR (400 MHz, D2O) δ 8.78 (1H, s, 
NCHN), 7.53 (1H, t, J = 1.7 Hz, NCHCHN), 7.48 (1H, t, J = 1.5 Hz, NCHCHN), 4.67 (1H, 
dd, J = 14.6, 2.5 Hz, H-6a), 4.49 (1H, d, J = 8.0 Hz, H-1), 4.42 (1H, dd, J = 14.7, 7.5 Hz, H-
6b), 3.96 – 3.88 (4H, m, NCH3 & OCHHCH2), 3.85 – 3.74 (2H, m, OCHHCH2 & H-5), 3.56 
– 3.43 (3H, m, OCH2CH2N3 & H-3), 3.30 – 3.20 (2H, m, H-2 & H-4), 2.81 (3H, s, SO2CH3); 
13C NMR (100 MHz, D2O) δ 136.8 (NCHN), 123.4 (NCHCHN), 123.1 (NCHCHN), 102.2 
(C-1), 75.3 (C-3), 73.1 (C-5), 72.8 (C-2), 70.3 (C-4), 68.6 (OCH2CH2), 50.3 (N3CH2), 49.8 
(C-6), 38.4 (SO2CH3), 35.7 (NCH3); ESI-HRMS for C12H20N5O5+ (MH+) calcd: 314.1459; 
found: 314.1460; νmax / cm-1 (film): 3367, 2918, 2165, 2107, 1644, 1577, 1425, 1167, 1040, 
834, 775; [∝]
 = -6.1 (c 0.2, MeOH). 
1-(2-azidoethyl)-6-(3-methyl-1H-imidazol-3-ium methanesulfonate)-6-deoxy-α-D-
mannopyranoside (13) 
 
To a solution of sugar 11 (228 mg, 0.70 mmol) in DMF (5 mL) was added 1-methylimidazole 
(277 µL, 3.48 mmol). The reaction mixture was stirred and heated to 80°C for 48 h until 
complete consumption of the starting material was observed by TLC. After cooling to room 
temperature, the reaction mixture was concentrated under reduced pressure, dried under high 
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vacuum and washed three times with a 1:1 hexane / diethyl ether (10 mL) mixture with 
sonication. After decantation, the oil was dried under vacuum, and purified by column 
chromatography (9:1 CH2Cl2 / MeOH then 65:35:2 CH2Cl2  / MeOH / H2O) to yield the 
product as a colourless solid (125 mg, 44 %). 1H NMR (400 MHz, D2O) δ 8.83 (1H, s, 
NCHN), 7.59 (1H, t, J = 1.9 Hz, NCHCHN), 7.48 (1H, t, J = 1.9 Hz, NCHCHN), 4.90 (1H, d, 
J = 1.7 Hz, H-1), 4.65 (1H, dd, J = 14.6, 2.4 Hz, H-6a), 4.41 (1H, dd, J = 14.6, 8.0 Hz, H-6b), 
3.98 (1H, dd, J = 3.4, 1.7 Hz, H-2), 3.94 – 3.87 (4H, m, H-5 & NCH3), 3.84 (1H, dd, J = 9.6, 
3.4 Hz, H-3), 3.62 (1H, ddd, J = 10.5, 5.9, 2.9 Hz, OCHHCH2), 3.57 – 3.43 (3H, m, 
OCHHCH2, H-4 & CH2CHHN3), 3.40 – 3.32 (1H, m, CH2CHHN3), 2.81 (3H, s, SO2CH3); 
13C NMR (101 MHz, D2O) δ 136.9 (NCHN), 123.4 (NCHCHN), 123.0 (NCHCHN), 99.9 (C-
1), 70.8 (C-5), 70.1 (C-3), 69.7 (C-2), 67.4 (C-4), 66.3 (OCH2CH2), 50.0 (N3CH2), 49.9 (C-
6), 38.4 (SO2CH3), 35.7 (NCH3); ESI-HRMS for C12H20N5O5+ (M+) calcd: 314.1459; found: 
314.1473; νmax / cm-1 (film): 3382, 2932, 2104, 1652, 1548, 1426, 1170, 1133, 1103, 1041, 
961, 894, 776; [∝]
 = +24.3 (c 1.9, MeOH). 
bis-N,N'-(N,N-dimethylpropylamine)-1,4,5,8-naphthalenetetracarboxylic diimide (S7) 
NN
O
OO
O
N
N
 
To a solution of 3-dimethylaminopropylamine (0.235 ml, 1.868 mmol) in toluene (10 ml) was 
added 1,4,5,8-Naphthalenetetracarboxylic dianhydride (NTCDA) (102 mg, 0.380 mmol) to 
give a yellow suspension. The reaction was heated to 145°C for 18 h until the reaction was 
determined to be complete by LC-MS (MH = 437). The solvent was removed in vacuo and 
purified by flash chromatography (CH2Cl2 to 9:1 CH2Cl2 / MeOH) to yield the product as a 
yellow solid (115 mg, 69 %). 1H NMR (400 MHz, CDCl3) δ 8.76 (4H, s, Ar-H), 4.27 (4H, t, 
J = 7.5 Hz,  C(O)NCH2CH2), 2.44 (4H, t, J = 7.1 Hz, CH3NCH2CH2), 2.23 (12H, s, NCH3), 
1.92 (4H, p, J = 7.3 Hz, CH2CH2CH2). 13C NMR (101 MHz, CDCl3) δ 162.4 (C=O), 130.4 
(Ar-CH), 126.2 (Ar-C), 56.7 (CH3NCH2CH2), 44.8 (NCH3), 38.8 (C(O)NCH2CH2), 25.5 
(CH2CH2CH2). Proton and carbon NMR were consistent with literature data.19 
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bis-N,N'-(N,N-dimethylpropan-1-aminium trifluoroacetate)-1,4,5,8-
naphthalenetetracarboxylic diimide (7) 
 
To a solution of S7 (28 mg, 0.07 mmol) in water (2 ml) was added TFA (100 μL) and stirred 
at rt for 1 min until all of the yellow solid had dissolved. The sample was then purified by 
reverse-phase flash chromatography (95:5 to 5:95 water + 0.1 % TFA/ MeCN) to yield the 
product as a colourless solid (32 mg, 74 %). 1H NMR (400 MHz, D2O) δ 8.65 (4H, s, Ar-H), 
4.26 (4H, t, J = 6.8 Hz, C(O)NCH2), 3.34 - 3.25 (4H, m, CH3NCH2), 2.93 (12H, s, NCH3), 
2.21 (4H, q, J = 7.3 Hz, CH2CH2CH2). 13C NMR (101 MHz, D2O) δ 163.9 (C=O), 130.6 (Ar-
CH), 125.7 (Ar-C), 54.9 (CH3NCH2), 42.3 (NCH3), 37.1 (C(O)NCH2), 22.4 (CH2CH2CH2). 
19F NMR (376 MHz, D2O) δ -75.60 (TFA). ESI-HRMS for C24H30N4O42+ (M+) calcd: 
219.1128; found: 219.1136; νmax / cm-1 (film): 2973, 2886, 1702, 1663, 1582, 1455, 1377, 
1336, 1247, 1174, 1126, 1054, 830, 799, 768, 720; HPLC (280 nm) tR: 18.4 min, purity: 99 
%.  
bis-N,N'-(3-(4-methyl-1-piperazine-1,2-diium trifluoroacetate)propyl)-1,4,5,8-
naphthalenetetracarboxylic diimide (6) 
 
To a solution of 1-(3-aminopropyl)-4-methylpiperazine (160 µL, 0.94 mmol) in toluene (10 
mL) was added NTCDA (51 mg, 0.19 mmol). The reaction mixture was heated to reflux for 
17 h until LC-MS showed the reaction was complete (MH = 548). The solution was cooled to 
room temperature, the solvent was removed in vacuo and purified by reverse-phase flash 
chromatography (90:10 to 5:95 water + 0.1 % TFA/ MeCN) to yield the product as a light 
pink solid (139 mg, 74 %). 1H NMR (400 MHz, D2O) δ 8.60 (4H, s, Ar-H), 4.27 (4H, t, J = 
6.9 Hz, (C=O)NCH2CH2), 3.71 (16H, br s, NCH2CH2N), 3.50 - 3.43 (4H, m, 
NCH2CH2CH2NC(O)), 3.05 (6H, s, NCH3), 2.26 (4H, p, J = 7.8 Hz, CH2CH2CH2); 13C NMR 
(101 MHz, D2O) δ 164.1 (C=O), 162.8 (q, J = 35.5 Hz, CF3C=O), 131.1 (Ar-CH), 126.0 (Ar-
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C), 116.3 (q, J = 291.8 Hz, CF3), 54.6 (NCH2CH2CH2NC(O)), 50.3 (NCH2CH2N), 48.8 
(NCH2CH2N), 42.8 (NCH3), 37.7 ((C=O)NCH2CH2), 22.3 (CH2CH2CH2); 19F NMR (376 
MHz, D2O) δ -75.58 (TFA); ESI-HRMS for C30H40N6O42+ (M+) calcd: 274.1550; found: 
274.1158; νmax / cm-1 (film): 3008, 1702, 1672, 1659, 1581, 1454, 1406, 1375, 1247, 1194, 
1170, 1103, 1074, 1040, 1017, 972, 962, 885, 850, 832, 795, 764, 721, 626; HPLC (280 nm) 
tR: 26.1 min, purity: >99 %. 
bis-N,N'-(1-(2-ethyl)-3-methyl-1H-imidazol-3-ium chloride)-1,4,5,8-
naphthalenetetracarboxylic diimide (4) 
 
To a solution of amine S5 (54 mg, 0.25 mmol) and pyridine (100 µL, 0.92 mmol) in EtOH (5 
mL) and acetonitrile (2 mL) was added NTCDA (23 mg, 0.08 mmol). The reaction mixture 
was heated to reflux for 4 h until complete consumption of the starting materials was 
observed by TLC. After cooling to room temperature, the brown solid was filtered off, 
washed with EtOH (5 mL) and dried under vacuum to yield the product as a colourless solid 
(11 mg, 23 %). 1H NMR (400 MHz, DMSO-d6) δ 9.21 (2H, s, NCHN), 8.66 (4H, s, Ar-H) 
7.87 (2H, app s, NCHCHN), 7.66 (2H, app  s, NCHCHN), 4.55 (4H, s, NCH2CH2N), 4.49 
(4H, app s, NCH2CH2N), 3.80 (6H, app s, CH3); 13C NMR (126 MHz, DMSO-d6) δ 163.29 
(C=O), 137.69 (NCHN), 130.98 (CH), 126.79 (C), 124.3 (C), 123.91 (NCHCHN), 123.55 
(NCHCHN), 47.87 (NCH2CH2N), 40.99 (NCH2CH2N), 36.20 (NCH3); ESI-HRMS for 
C26H24N6O42+ (M2+) calcd: 242.0924; found: 242.0919; νmax / cm-1 (film): 3395, 3164, 
31101705, 1667, 1582, 1456, 1379, 1340, 1255, 1168, 1019, 889, 802, 767, 726, 655; HPLC 
(280 nm) tR: 21.0 min, purity: 95 %. 
bis-N,N'-(1-(3-propyl)-3-methyl-1H-imidazol-3-ium chloride)-1,4,5,8-
naphthalenetetracarboxylic diimide (5) 
 
To a solution of amine S6 (57 mg, 0.25 mmol) and pyridine (100 µL, 0.92 mmol) in EtOH (5 
mL) and acetonitrile (2 mL) was added NTCDA (23 mg, 0.08 mmol). The reaction mixture 
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was heated to reflux for 19 h until complete consumption of the starting materials was 
observed by TLC. After cooling to room temperature, the brown solid was filtered off, 
washed with EtOH (5 mL) and dried under vacuum to yield the product as a colourless solid 
(25 mg, 51 %). 1H NMR (400 MHz, DMSO-d6) δ 9.10 (2H, s, NCHN), 8.70 (4H, s, Ar-H), 
7.79 (2H, s, NCHCHN), 7.70 (2H, s, NCHCHN), 4.30 (4H, t, J = 7.3 Hz, NCH2CH2), 4.12 
(4H, t, J = 6.6 Hz, CH2CH2N), 3.85 (6H, s, CH3), 2.25 (4H, p, J = 6.7 Hz, CH2CH2CH2); 13C 
NMR (126 MHz, DMSO-d6) δ 163.37 (C=O), 137.12 (NCHN), 130.89 (CH), 126.89 (C), 
126.68 (C), 124.05 (NCHCHN), 122.71 (NCHCHN), 47.34 (NCH2CH2), 37.65 (CH2CH2N), 
36.21 (NCH3), 28.71 (CH2CH2CH2); ESI-HRMS for C28H28N6O42+ (M2+) calcd: 256.1081; 
found: 256.1076; νmax / cm-1 (film): 3410, 3164, 3113, 2975, 1701, 1657, 1579, 1460, 1336, 
1249, 1173, 1056, 970, 852, 768, 746, 660; HPLC (280 nm) tR: 25.6 min, purity: 96 %. 
bis-N,N'-(2-ethyl-β-D-glucopyranoside)-1,4,5,8-naphthalenetetracarboxylic diimide (1) 
 
To a solution of 2-aminoethyl-β-D-Glucopyranoside18 (41 mg, 0.18 mmol) in anhydrous 
EtOH (5 mL) was added NTCDA (22 mg, 0.08 mmol). The reaction mixture was stirred and 
heated to reflux for 16 h until the reaction was determined to be complete by MALDI (MNa+ 
= 701). After cooling to room temperature, the mixture was cooled to 0°C and the resulting 
precipitate was filtered, washed with cold ethanol (10 mL) and diethyl ether (10 mL), to yield 
the product as a colourless solid (20 mg, 37 %). 1H NMR (500 MHz, D2O) δ 8.48 (1H, s, Ar-
H), 4.53 - 4.46 (2H, m, CH2CHHN), 4.48 (2H, d, J = 7.9 Hz, H-1), 4.39 – 4.30 (2H, m, 
CH2CHHN), 4.27 – 4.19 (2H, m, H-6a), 4.05 (2H, dt, J = 10.6, 5.0 Hz, H-6b), 3.73 (2H, dd, J 
= 12.2, 1.9 Hz, OCHHCH2), 3.50 (2H, dd, J = 12.3, 5.9 Hz, OCHHCH2), 3.47 – 3.38 (4H, m, 
H-5 & H-3), 3.32 – 3.21 (4H, m, H-4 & H-2); 13C NMR (126 MHz, CDCl3) δ 163.75 (C=O), 
130.96 (CH), 125.72 (C), 125.52 (C), 102.36 (C-1), 75.79 (C-5), 75.56 (C-3), 72.98 (C-2), 
69.53 (C-4), 66.68 (C-6), 60.65 (OCH2CH2N), 40.11 (NCH2CH2O); ESI-HRMS for 
C30H34N2NaO16+ (MNa+) calcd: 701.1801; found: 701.1800; νmax / cm-1 (film): 3342, 2955, 
2922, 2853, 1728, 1635, 1461, 1377, 1260, 1071;  [∝]
 = -280 (c 0.1, MeOH); HPLC (280 
nm) tR: 18.3 min, purity: 98 %. 
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bis-N,N'-(2-ethyl-6-(3-methyl-1H-imidazol-3-ium formate)-6-deoxy-β-D-
glucopyranoside)-1,4,5,8-naphthalenetetracarboxylic diimide (2) 
N N
O
O O
O
O O
O
HO OH
ON
HO OH
OH
N
HO
N
N O
O
• 2
 
To a solution of sugar 12 (48 mg, 0.15 mmol) in ethanol with 5% HCl (5 mL) was added 
palladium catalyst (10% Pd-C, 15 mg). The reaction mixture was left stirring  at room 
temperature under a under a H2 atmosphere at 1 atm for 2 h until complete consumption of 
starting materials was observed by TLC. The resulting mixture was then filtered through a 
Celite bed and washed with MeOH. The filtrate was concentrated in vacuo to give the 
intermediate amine as a yellow oil (45 mg). ESI-HRMS for C12H22N3O5+ (MH+) calcd: 
288.1554; found: 288.1557. Without further purification, a portion of the dry mixture (15 mg) 
was directly taken to the next step and NTCDA (4 mg, 0.02 mmol) and triethylamine (50 µL, 
0.36 mmol) were added and dissolved in anhydrous EtOH (5 mL). The reaction mixture was 
stirred and heated to reflux. After 16 h, a green fluorescent spot was observed by TLC and 
MALDI analysis revealed formation of the desired product (M+ = 808). After cooling to room 
temperature, the solvent was removed in vacuo and the resulting dark oil was purified by 
preparative reverse-phase HPLC to yield the product as a light brown solid (7.4 mg, 55 %). 
1H NMR (500 MHz, D2O) δ 8.78 (2H, s, NCHN), 8.71 (4H, s, Ar-H), 8.46 (2H, br s, 
HCOO), 7.48 (4H, s, NCHCHN), 4.62 (2H, d, J = 13.1 Hz, H-6a), 4.47 (2H, d, J = 7.9 Hz, H-
1), 4.45 – 4.36 (4H, m, OCH2CH2N), 4.30 (2H, dd, J = 14.7, 7.8 Hz, H-6b), 4.10 (2H dt, J = 
11.6, 6.1 Hz, OCHHCH2N), 4.00 – 3.91 (8H, m, OCHHCH2N & NCH3), 3.79 – 3.72 (2H, m, 
H-5), 3.47 (2H, t, J = 9.2 Hz, H-3), 3.22 (2H, t, J = 8.9 Hz, H-2), 3.18 (2H, t, J = 9.3 Hz, H-
4); 13C NMR (126 MHz, D2O) δ 171.0 (HCOO), 164.3 (C=O), 136.8 (NCHN), 131.0 (CH), 
126.2 (C), 126.1 (C), 123.5 (NCHCHN), 123.1 (NCHCHN), 102.5 (C-1), 75.2 (C-3), 73.3 
(C-5), 72.8 (C-2), 70.4 (C-4), 66.6 (OCH2CH2N), 49.9 (C-6), 40.0 (NCH2CH2O), 35.8 
(NCH3); ESI-HRMS for C38H44N6O142+ (M2+) calcd: 404.1452; found: 404.1456; νmax / cm-1 
(film): 3368, 1706, 1665, 1583, 1345, 1080; [∝]
 = +21 (c 0.1, MeOH); HPLC (280 nm) tR: 
25.5 min, purity: 96 %. 
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bis-N,N'-(2-ethyl-6-(3-methyl-1H-imidazol-3-ium formate)-6-deoxy-α-D-
mannopyranoside)-1,4,5,8-naphthalenetetracarboxylic diimide (3) 
 
To a solution of sugar 13 (55 mg, 0.14 mmol) in ethanol with 5% HCl (10 mL) was added 
palladium catalyst (10% Pd-C, 17 mg). The reaction mixture was hydrogenated at 1 atm for 
1.5 h until complete consumption of the starting material was observed by TLC. The resulting 
mixture was then filtered through a Celite bed and washed with MeOH. The filtrate was 
concentrated in vacuo to give the intermediate amine as a yellow oil (49 mg). To the crude 
intermediate (16 mg), NTCDA (4 mg, 0.02 mmol) and triethylamine (20 µL, 0.15 mmol) was 
added and dissolved in anhydrous EtOH (5 mL). The reaction mixture was stirred and heated 
to 80°C. After 17 h, a green fluorescent spot was observed by TLC and MALDI analysis 
revealed formation of the desired product (M+ = 808). After cooling to room temperature, the 
solvent was removed in vacuo and the resulting dark oil was purified by preparative reverse-
phase HPLC to yield the product as a light brown solid (8.2 mg, 60 %). 1H NMR (500 MHz, 
D2O) δ 8.82 (2H, s, NCHN), 8.60 (4H, s, Ar-H), 8.40 (2H, br s, HCOO), 7.49 (2H, t, J = 1.8 
Hz, NCHCHN), 7.46 (2H, t, J = 1.8 Hz, NCHCHN), 4.98 (2H, d, J = 1.6 Hz, H-1), 4.52 (2H, 
dd, J = 14.6, 2.3 Hz, H-6a), 4.42 (2H, ddd, J = 13.9, 7.9, 4.9 Hz, OCH2CHHN), 4.34 (2H, dd, 
J = 14.6, 8.0 Hz, H-6b), 4.22 (2H, dt, J = 14.0, 4.9 Hz, OCH2CHHN), 3.96 (6H, s, NCH3), 
3.90 (1H, dd, J = 3.4, 1.7 Hz, H-2), 3.79 (2H, dt, J = 10.9, 4.9 Hz, OCHHCH2N), 3.76 – 3.68 
(4H, m, H-5 & OCHHCH2N), 3.66 (2H, dd, J = 9.6, 3.4 Hz, H-3), 3.48 (2H, t, J = 9.7 Hz, H-
4); 13C NMR (126 MHz, D2O) δ 169.4 (HCOO), 163.8 (C=O), 136.9 (NCHN), 131.1 (CH), 
125.9 (C), 125.8 (C), 123.5 (NCHCHN), 122.9 (NCHCHN), 99.3 (C-1), 70.9 (C-5), 70.2 (C-
3), 69.7 (C-2), 67.2 (C-4), 63.7 (NCH2CH2O), 49.8 (C-6), 39.5 (NCH2CH2O), 35.8 (NCH3); 
ESI-HRMS for C38H44N6O142+ (M2+) calcd: 404.1452; found: 404.1468; νmax / cm-1 (film): 
3350, 3159, 2919, 2781, 2699, 1703, 1666, 1597, 1455, 1342, 1243, 1169, 1134, 1049, 961, 
766; [∝]
 = 34.2 (c 0.3, MeOH); HPLC (280 nm) tR: 25.9 min, purity: 99 %. 
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